Journal article

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Francesca J Torriani, Maribel Rodriguez-Torres, Jürgen K Rockstroh, Eduardo Lissen, Juan Gonzalez-García, Adriano Lazzarin, Giampiero Carosi, Joseph Sasadeusz, Christine Katlama, Julio Montaner, Hoel Sette, Sharon Passe, Jean De Pamphilis, Frank Duff, Uschi Marion Schrenk, Douglas T Dieterich, undefined APRICOT Study Group

New England Journal of Medicine | Published : 2004


BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 microg per week) plus..

View full abstract

University of Melbourne Researchers